![Abnormal center of mass control during balance: a new biomarker of falls in people with Parkinson's disease | bioRxiv Abnormal center of mass control during balance: a new biomarker of falls in people with Parkinson's disease | bioRxiv](https://www.biorxiv.org/content/biorxiv/early/2021/01/11/2020.01.27.921379/F1.large.jpg)
Abnormal center of mass control during balance: a new biomarker of falls in people with Parkinson's disease | bioRxiv
![Identification of SR8278, a Synthetic Antagonist of the Nuclear Heme Receptor REV-ERB | ACS Chemical Biology Identification of SR8278, a Synthetic Antagonist of the Nuclear Heme Receptor REV-ERB | ACS Chemical Biology](https://pubs.acs.org/cms/10.1021/cb1002575/asset/images/large/cb-2010-002575_0005.jpeg)
Identification of SR8278, a Synthetic Antagonist of the Nuclear Heme Receptor REV-ERB | ACS Chemical Biology
![Gefapixant, a P2X3 receptor antagonist, for the treatment of refractory or unexplained chronic cough: a randomised, double-blind, controlled, parallel-group, phase 2b trial - The Lancet Respiratory Medicine Gefapixant, a P2X3 receptor antagonist, for the treatment of refractory or unexplained chronic cough: a randomised, double-blind, controlled, parallel-group, phase 2b trial - The Lancet Respiratory Medicine](https://www.thelancet.com/cms/asset/35f94457-9b33-4a76-9cb4-4153f6cf4a34/gr1.jpg)
Gefapixant, a P2X3 receptor antagonist, for the treatment of refractory or unexplained chronic cough: a randomised, double-blind, controlled, parallel-group, phase 2b trial - The Lancet Respiratory Medicine
Impact of an Adenosine A2A Receptor Agonist and Antagonist on Binding of the Dopamine D2 Receptor Ligand [11C]raclopride in the Rodent Striatum | Molecular Pharmaceutics
![JCM | Free Full-Text | Finerenone: Questions and Answers—The Four Fundamental Arguments on the New-Born Promising Non-Steroidal Mineralocorticoid Receptor Antagonist JCM | Free Full-Text | Finerenone: Questions and Answers—The Four Fundamental Arguments on the New-Born Promising Non-Steroidal Mineralocorticoid Receptor Antagonist](https://www.mdpi.com/jcm/jcm-12-03992/article_deploy/html/images/jcm-12-03992-g001-550.jpg)
JCM | Free Full-Text | Finerenone: Questions and Answers—The Four Fundamental Arguments on the New-Born Promising Non-Steroidal Mineralocorticoid Receptor Antagonist
![Abnormal center of mass control during balance: a new biomarker of falls in people with Parkinson's disease | bioRxiv Abnormal center of mass control during balance: a new biomarker of falls in people with Parkinson's disease | bioRxiv](https://www.biorxiv.org/content/biorxiv/early/2021/01/11/2020.01.27.921379/F2.large.jpg)
Abnormal center of mass control during balance: a new biomarker of falls in people with Parkinson's disease | bioRxiv
![Efficacy and safety of landiolol, an ultra-short-acting β1-selective antagonist, for treatment of sepsis-related tachyarrhythmia (J-Land 3S): a multicentre, open-label, randomised controlled trial - The Lancet Respiratory Medicine Efficacy and safety of landiolol, an ultra-short-acting β1-selective antagonist, for treatment of sepsis-related tachyarrhythmia (J-Land 3S): a multicentre, open-label, randomised controlled trial - The Lancet Respiratory Medicine](https://www.thelancet.com/cms/attachment/a1f060f4-7806-40bf-839a-56ef24f6f8d6/gr1.gif)
Efficacy and safety of landiolol, an ultra-short-acting β1-selective antagonist, for treatment of sepsis-related tachyarrhythmia (J-Land 3S): a multicentre, open-label, randomised controlled trial - The Lancet Respiratory Medicine
![Stimulation of the Locus Ceruleus Modulates Signal-to-Noise Ratio in the Olfactory Bulb | Journal of Neuroscience Stimulation of the Locus Ceruleus Modulates Signal-to-Noise Ratio in the Olfactory Bulb | Journal of Neuroscience](https://www.jneurosci.org/content/jneuro/37/48/11605/F1.large.jpg)